Integrated DNA Technologies Release: Exploring the Next Generation of Oligonucleotide Technologies at American Society of Human Genetics
Published: Oct 15, 2013
CORALVILLE, IA – 15th October 2013 – Integrated DNA Technologies (IDT), the world leader in oligonucleotide synthesis, will be attending the American Society of Human Genetics (ASHG), in Boston (US), October 22-26. Delegates of ASHG can also join Director of Product Development at IDT, Dr Scott Rose, for a presentation entitled “Building clinically relevant custom enrichment panels using IDT’s xGen® Lockdown® probes.” The talk will take place in the Exhibition Theatre on October 23 at 10.15 am and provides researchers with the chance to learn how they can improve the performance of their targeted enrichment protocols for clinical research.
Vastly improving the efficiency of next generation sequencing (NGS), target enrichment strategies are vital for making this powerful technology an accessible tool for clinical applications. In-solution hybridization is the most effective approach, and IDT is at the forefront of developing novel oligonucleotide technologies for improving these protocols. As a novel alternative to array-synthesis platforms, xGen Lockdown probes offer unrivalled flexibility in the creation and modification of custom panels. Enhancing the percentage of on-target capture when used in combination with libraries incorporating adaptors, IDT has also developed a new generation of proprietary modified blocking oligonucleotides. The xGen Universal Blocking Oligos block nonspecific hybridisation between the library and the adaptor sequence, and has been shown to improve “on-target capture” by 10-25% when using libraries made with TruSeqTM adaptors.
For more information please visit IDT at ASHG, or www.idtdna.com. Follow us on twitter @idtdna for real-time updates and insights.
Integrated DNA Technologies (IDT) is the largest supplier of custom nucleic acids in the world, serving academic, government, and commercial researchers in biotechnology, clinical diagnostics, and pharmaceutical development. IDT's primary business is the manufacture of custom, synthetic DNA and RNA oligonucleotides. Today, IDT synthesizes and ships an average of 36,000 custom oligos per day to more than 86,000 customers worldwide. IDT manufacturing locations include facilities in Coralville, Iowa; San Diego, Calif.; Leuven, Belgium; and Singapore. For more information visit www.idtdna.com.
Integrated DNA Technologies
800-328-2661 (US & Canada)
+1 319-626-8400 (outside US)
Help employers find you! Check out all the jobs and post your resume.